FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1425-1435 April 7, 2005 Number 14 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Pitt, B. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Previous trials have demonstrated that lowering low-density lipoprotein (LDL) cholesterol levels below currently recommended levels is beneficial in patients with acute coronary syndromes. We prospectively assessed the efficacy and safety of lowering LDL cholesterol levels below 100 mg per deciliter (2.6 mmol per liter) in patients with stable coronary heart disease (CHD).

Methods A total of 10,001 patients with clinically evident CHD and LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) were randomly assigned to double-blind therapy and received either 10 mg or 80 mg of atorvastatin per day. Patients were followed for a median of 4.9 years. The primary end point was the occurrence of a first major cardiovascular event, defined as death from CHD, nonfatal non–procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke.

Results The mean LDL cholesterol levels were 77 mg per deciliter (2.0 mmol per liter) during treatment with 80 mg of atorvastatin and 101 mg per deciliter (2.6 mmol per liter) during treatment with 10 mg of atorvastatin. The incidence of persistent elevations in liver aminotransferase levels was 0.2 percent in the group given 10 mg of atorvastatin and 1.2 percent in the group given 80 mg of atorvastatin (P<0.001). A primary event occurred in 434 patients (8.7 percent) receiving 80 mg of atorvastatin, as compared with 548 patients (10.9 percent) receiving 10 mg of atorvastatin, representing an absolute reduction in the rate of major cardiovascular events of 2.2 percent and a 22 percent relative reduction in risk (hazard ratio, 0.78; 95 percent confidence interval, 0.69 to 0.89; P<0.001). There was no difference between the two treatment groups in overall mortality.

Conclusions Intensive lipid-lowering therapy with 80 mg of atorvastatin per day in patients with stable CHD provides significant clinical benefit beyond that afforded by treatment with 10 mg of atorvastatin per day. This occurred with a greater incidence of elevated aminotransferase levels.

Source Information

From the State University of New York Health Science Center, Brooklyn (J.C.L.); the University of Texas Southwestern Medical Center, Dallas (S.M.G.); San Francisco General Hospital, San Francisco (D.D.W.); Pfizer, Groton, Conn. (C.S.); the Heart Research Institute, Sydney (P.B.); Institut Pasteur, Lille, France (J.-C.F.); Weill Medical College of Cornell University, New York (A.M.G.); Universitätsklinikum Eppendorf, Hamburg, Germany (H.G.); Academic Medical Center, University of Amsterdam, Amsterdam (J.J.P.K.); the University of Glasgow, Glasgow, United Kingdom (J.S.); and Emory University School of Medicine, Atlanta (N.K.W.).

This article was published at www.nejm.org on March 8, 2005.

Address reprint requests to Dr. LaRosa at the State University of New York Health Science Center, 450 Clarkson Ave., Brooklyn, NY 11203, or at jclarosa{at}downstate.edu.

Full Text of this Article

Related Letters:

Intensive Lipid Lowering with Atorvastatin in Coronary Disease
Auer J., Lamm G., Eber B., Cannon C. P., Murphy S. A., Braunwald E., Ravnskov U., Rosch P. J., Sutter M. C., Modest G. A., Southern W., LaRosa J. C., Grundy S. M., Waters D. D.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:93-96, Jul 7, 2005. Correspondence

This article has been cited by other articles:

• The SEARCH Collaborative Group, (2008). SLCO1B1 Variants and Statin-Induced Myopathy -- A Genomewide Study. NEJM 0: NEJMoa0801936v1-1 [Abstract] [Full Text]  
• Settergren, M., Bohm, F., Ryden, L., Pernow, J. (2008). Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J 29: 1753-1760 [Abstract] [Full Text]  
• Pedersen, T. R. (2008). Overview of clinical trials on calcific aortic stenosis. Eur Heart J Suppl 10: E31-E40 [Abstract] [Full Text]  
• Kastelein, J. J.P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., Szarek, M., LaRosa, J. C., Pedersen, T. R., Grundy, S. M., for the TNT and IDEAL Study Groups, (2008). Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation 117: 3002-3009 [Abstract] [Full Text]  
• Goldstein, L. B., Amarenco, P., Szarek, M., Callahan, A. III, Hennerici, M., Sillesen, H., Zivin, J. A., Welch, K.M.A., On behalf of the SPARCL Investigators, (2008). Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 70: 2364-2370 [Abstract] [Full Text]  
• Bloomgarden, Z. T. (2008). Cardiovascular Disease in Diabetes. Diabetes Care 31: 1260-1266 [Full Text]  
• Hausenloy, D J, Yellon, D M (2008). Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 94: 706-714 [Abstract] [Full Text]  
• Shah, S. J., Waters, D. D., Barter, P., Kastelein, J. J.P., Shepherd, J., Wenger, N. K., DeMicco, D. A., Breazna, A., LaRosa, J. C. (2008). Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. J Am Coll Cardiol 51: 1938-1943 [Abstract] [Full Text]  
• Ky, B., Burke, A., Tsimikas, S., Wolfe, M. L., Tadesse, M. G., Szapary, P. O., Witztum, J. L., FitzGerald, G. A., Rader, D. J. (2008). The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. J Am Coll Cardiol 51: 1653-1662 [Abstract] [Full Text]  
• Ambrose, J. A. (2008). In Search of the "vulnerable plaque": can it be localized and will focal regional therapy ever be an option for cardiac prevention?. J Am Coll Cardiol 51: 1539-1542 [Abstract] [Full Text]  
• Shepherd, J., Kastelein, J. J.P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., Wenger, N. K., for the TNT (Treating to New Targets) Investigator, (2008). Intensive Lipid Lowering With Atorvastatin in Patients With Coronary Heart Disease and Chronic Kidney Disease: The TNT (Treating to New Targets) Study. J Am Coll Cardiol 51: 1448-1454 [Abstract] [Full Text]  
• Kastelein, J. J.P., Akdim, F., Stroes, E. S.G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F.H., Visseren, F. L.J., Sijbrands, E. J.G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., de Groot, E., the ENHANCE Investigators, (2008). Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. NEJM 358: 1431-1443 [Abstract] [Full Text]  
• Torabi, A., Cleland, J. G.F., Khan, N. K., Loh, P. H., Clark, A. L., Alamgir, F., Caplin, J. L., Rigby, A. S., Goode, K. (2008). The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J 29: 859-870 [Abstract] [Full Text]  
• Arca, M., Conti, B., Montali, A., Pignatelli, P., Campagna, F., Barilla, F., Tanzilli, G., Verna, R., Vestri, A., Gaudio, C., Violi, F. (2008). C242T Polymorphism of NADPH Oxidase p22phox and Recurrence of Cardiovascular Events in Coronary Artery Disease. Arterioscler. Thromb. Vasc. Bio. 28: 752-757 [Abstract] [Full Text]  
• Wenger, N K, Lewis, S J, Welty, F K, Herrington, D M, Bittner, V, on behalf of the TNT Steering Committee and Invest, (2008). Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart 94: 434-439 [Abstract] [Full Text]  
• Athyros, V. G., Kakafika, A. I., Tziomalos, K., Karagiannis, A., Mikhailidis, D. P. (2008). CORONA, Statins, and Heart Failure: Who Lost the Crown?. ANGIOLOGY 59: 5-8  
• Birnbaum, Y., Lin, Y., Ye, Y., Merla, R., Perez-Polo, J. R., Uretsky, B. F. (2008). Pretreatment With High-Dose Statin, But Not Low-Dose Statin, Ezetimibe, or the Combination of Low-Dose Statin and Ezetimibe, Limits Infarct Size in the Rat. J CARDIOVASC PHARMACOL THER 13: 72-79 [Abstract]  
• Josan, K. MD, Majumdar, S. R. MD MPH, McAlister, F. A. MD MSc (2008). The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178: 576-584 [Abstract] [Full Text]  
• Bittner, V., Herrington, D., Wenger, N. (2008). Analyzing the Results of the Treating to New Targets Study. ANN INTERN MED 148: 322-323 [Full Text]  
• Donner-Banzhoff, N., Sonnichsen, A. (2008). Strategies for prescribing statins. BMJ 336: 288-289 [Full Text]  
• Zannad, F., Stough, W. G., Pitt, B., Cleland, J. G.F., Adams, K. F., Geller, N. L., Torp-Pedersen, C., Kirwan, B.-A., Follath, F. (2008). Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. Eur Heart J 29: 413-421 [Abstract] [Full Text]  
• Richards, N., Harris, K., Whitfield, M., O'Donoghue, D., Lewis, R., Mansell, M., Thomas, S., Townend, J., Eames, M., Marcelli, D. (2008). Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes. Nephrol Dial Transplant 23: 549-555 [Abstract] [Full Text]  
• Iakoubova, O. A., Sabatine, M. S., Rowland, C. M., Tong, C. H., Catanese, J. J., Ranade, K., Simonsen, K. L., Kirchgessner, T. G., Cannon, C. P., Devlin, J. J., Braunwald, E. (2008). Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.. J Am Coll Cardiol 51: 449-455 [Abstract] [Full Text]  
• Superko, H. R., King, S. III (2008). Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required. Circulation 117: 560-568 [Full Text]  
• Grundy, S. M. (2008). Promise of Low-Density Lipoprotein-Lowering Therapy for Primary and Secondary Prevention. Circulation 117: 569-573 [Full Text]  
• Grundy, S. M. (2008). Thyroid mimetic as an option for lowering low-density lipoprotein. Proc. Natl. Acad. Sci. USA 105: 409-410 [Full Text]  
• Nesto, R. W. (2008). LDL Cholesterol Lowering in Type 2 Diabetes: What Is the Optimum Approach?. Clin. Diabetes 26: 8-13 [Abstract] [Full Text]  
• Anand, D. V., Lim, E., Darko, D., Bassett, P., Hopkins, D., Lipkin, D., Corder, R., Lahiri, A. (2007). Determinants of Progression of Coronary Artery Calcification in Type 2 Diabetes: Role of Glycemic Control and Inflammatory/Vascular Calcification Markers. J Am Coll Cardiol 50: 2218-2225 [Abstract] [Full Text]  
• Holman, J. R. (2007). Some Docs in Denial About Statin Side Effects. DOC News 4: 1-12 [Full Text]  
• Preston, R. A., Harvey, P., Herfert, O., Dykstra, G., Jukema, J. W., Sun, F., Gillen, D. (2007). A Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacodynamic Interaction of Coadministered Amlodipine and Atorvastatin in 1660 Patients With Concomitant Hypertension and Dyslipidemia: The Respond Trial. J Clin Pharmacol 47: 1555-1569 [Abstract] [Full Text]  
• Chaturvedi, S., Turan, T. N., Lynn, M. J., Kasner, S. E., Romano, J., Cotsonis, G., Frankel, M., Chimowitz, M. I., For the WASID Study Group, (2007). Risk factor status and vascular events in patients with symptomatic intracranial stenosis. Neurology 69: 2063-2068 [Abstract] [Full Text]  
• Shepherd, J., Kastelein, J. J.P., Bittner, V., Deedwania, P., Breazna, A., Dobson, S., Wilson, D. J., Zuckerman, A., Wenger, N. K., for the Treating to New Targets Investigators, (2007). Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart Disease: The Treating to New Targets (TNT) Study. CJASN 2: 1131-1139 [Abstract] [Full Text]  
• Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., Kwiterovich, P. O. Jr (2007). Beyond Low-Density Lipoprotein Cholesterol: Defining the Role of Low-Density Lipoprotein Heterogeneity in Coronary Artery Disease. J Am Coll Cardiol 50: 1735-1741 [Abstract] [Full Text]  
• Marschner, I. C., Simes, R. J., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. Am J Epidemiol 166: 824-831 [Abstract] [Full Text]  
• Cahoon, W. D Jr, Crouch, M. A (2007). Preprocedural Statin Therapy in Percutaneous Coronary Intervention. The Annals of Pharmacotherapy 41: 1687-1693 [Abstract] [Full Text]  
• Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J.P., Bittner, V., Fruchart, J.-C., the Treating to New Targets Investigators, (2007). HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events. NEJM 357: 1301-1310 [Abstract] [Full Text]  
• Blanco, M., Nombela, F., Castellanos, M., Rodriguez-Yanez, M., Garcia-Gil, M., Leira, R., Lizasoain, I., Serena, J., Vivancos, J., Moro, M. A., Davalos, A., Castillo, J. (2007). Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 69: 904-910 [Abstract] [Full Text]  
• Singh, I. M., Shishehbor, M. H., Ansell, B. J. (2007). High-Density Lipoprotein as a Therapeutic Target: A Systematic Review. JAMA 298: 786-798 [Abstract] [Full Text]  
• Stein, E. A. (2007). Statins and Children: Whom Do We Treat and When?. Circulation 116: 594-595 [Full Text]  
• Leeper, N. J., Ardehali, R., deGoma, E. M., Heidenreich, P. A. (2007). Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival. Circulation 116: 613-618 [Abstract] [Full Text]  
• Afilalo, J., Majdan, A. A, Eisenberg, M. J (2007). Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 93: 914-921 [Abstract] [Full Text]  
• Yu, C.-M., Zhang, Q., Lam, L., Lin, H., Kong, S.-L., Chan, W., Fung, J. W.-H., Cheng, K. K K, Chan, I. H.-S., Lee, S. W.-L., Sanderson, J. E, Lam, C. W.-K. (2007). Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 93: 933-939 [Abstract] [Full Text]  
• Choudhry, N. K, Levin, R., Winkelmayer, W. C (2007). Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart 93: 945-951 [Abstract] [Full Text]  
• Alsheikh-Ali, A. A., Maddukuri, P. V., Han, H., Karas, R. H. (2007). Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials. J Am Coll Cardiol 50: 409-418 [Abstract] [Full Text]  
• Wenger, N. K., Lewis, S. J., Herrington, D. M., Bittner, V., Welty, F. K., for the Treating to New Targets Study Steering Com, (2007). Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease. ANN INTERN MED 147: 1-9 [Abstract] [Full Text]  
• Brewster, L. M., van Montfrans, G. A. (2007). Letter by Brewster and van Montfrans Regarding Article, "Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials". Circulation 116: e7-e7 [Full Text]  
• Authors/Task Force Members, , Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A.A., Hasdai, D., Ohman, E. M., Wallentin, L., Wijns, W., ESC Committee for Practice Guidelines (CPG), , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Kristensen, S. D., Widimsky, P., McGregor, K., Sechtem, U., Tendera, M., Hellemans, I., Gomez, J. L. Z., Silber, S., Funck-Brentano, C., Document Reviewers, , Kristensen, S. D., Andreotti, F., Benzer, W., Bertrand, M., Betriu, A., De Caterina, R., DeSutter, J., Falk, V., Ortiz, A. F., Gitt, A., Hasin, Y., Huber, K., Kornowski, R., Lopez-Sendon, J., Morais, J., Nordrehaug, J. E., Silber, S., Steg, P. G., Thygesen, K., Tubaro, M., Turpie, A. G.G., Verheugt, F., Windecker, S. (2007). Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 28: 1598-1660 [Full Text]  
• Nogueira, J., Weir, M. (2007). The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. CJASN 2: 766-785 [Abstract] [Full Text]  
• Timmis, A. D, Feder, G., Hemingway, H. (2007). Prognosis of stable angina pectoris: why we need larger population studies with higher endpoint resolution. Heart 93: 786-791 [Abstract] [Full Text]  
• Kostapanos, M.S., Liberopoulos, E.N., Goudevenos, J.A., Mikhailidis, D.P., Elisaf, M.S. (2007). Do statins have an antiarrhythmic activity?. Cardiovasc Res 75: 10-20 [Abstract] [Full Text]  
• Lindgren, P., Graff, J., Olsson, A. G., Pedersen, T. J., Jonsson, B., on behalf of the IDEAL Trial Investigators, (2007). Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J 28: 1448-1453 [Abstract] [Full Text]  
• Tuzcu, E. M., Nicholls, S. J. (2007). Statins: Targeting Inflammation by Lowering Low-Density Lipoprotein?. J Am Coll Cardiol 49: 2010-2012 [Full Text]  
• Chan, P. S., Nallamothu, B. K., Gurm, H. S., Hayward, R. A., Vijan, S. (2007). Incremental Benefit and Cost-Effectiveness of High-Dose Statin Therapy in High-Risk Patients With Coronary Artery Disease. Circulation 115: 2398-2409 [Abstract] [Full Text]  
• (2007). Which statin, what dose?. DTB 45: 33-37 [Abstract] [Full Text]  
• Garg, A., Simha, V. (2007). Update on Dyslipidemia. J. Clin. Endocrinol. Metab. 92: 1581-1589 [Abstract] [Full Text]  
• Sassano, A., Katsoulidis, E., Antico, G., Altman, J. K., Redig, A. J., Minucci, S., Tallman, M. S., Platanias, L. C. (2007). Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells. Cancer Res. 67: 4524-4532 [Abstract] [Full Text]  
• Davidson, M. H., Robinson, J. G. (2007). Safety of Aggressive Lipid Management. J Am Coll Cardiol 49: 1753-1762 [Abstract] [Full Text]  
• Oktem, M., Esinler, I., Eroglu, D., Haberal, N., Bayraktar, N., Zeyneloglu, H. B. (2007). High-dose atorvastatin causes regression of endometriotic implants: a rat model. Hum Reprod 22: 1474-1480 [Abstract] [Full Text]  
• Kastelein, J. J.P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., Duggan, W. T., Bots, M. L., the RADIANCE 1 Investigators, (2007). Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. NEJM 356: 1620-1630 [Abstract] [Full Text]  
• Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., Chaitman, B. R., Shaw, L., Gosselin, G., Nawaz, S., Title, L. M., Gau, G., Blaustein, A. S., Booth, D. C., Bates, E. R., Spertus, J. A., Berman, D. S., Mancini, G.B. J., Weintraub, W. S., the COURAGE Trial Research Group, (2007). Optimal Medical Therapy with or without PCI for Stable Coronary Disease. NEJM 356: 1503-1516 [Abstract] [Full Text]  
• Song, J. C., Wang, C. C., Huang, Y.-C., Sanchez, J., Nguyen, T., Khan, S., Kim, M.-K., Li, P. (2007). Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population. Am J Health Syst Pharm 64: 767-772 [Abstract] [Full Text]  
• Crouse, J. R. III, Raichlen, J. S., Riley, W. A., Evans, G. W., Palmer, M. K., O'Leary, D. H., Grobbee, D. E., Bots, M. L., for the METEOR Study Group, (2007). Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals With Subclinical Atherosclerosis: The METEOR Trial. JAMA 297: 1344-1353 [Abstract] [Full Text]  
• Patel, T. N., Shishehbor, M. H., Bhatt, D. L. (2007). A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 28: 664-672 [Abstract] [Full Text]  
• Ray, J. G., Norris, C. M., Udell, J. A., Tsuyuki, R. T., McAlister, F. A., Knudtson, M. L., Ghali, W. A. (2007). Lipid-Lowering Therapy and Outcomes in Heart Failure. J CARDIOVASC PHARMACOL THER 12: 27-35 [Abstract]  
• Deedwania, P., Stone, P. H., Bairey Merz, C. N., Cosin-Aguilar, J., Koylan, N., Luo, D., Ouyang, P., Piotrowicz, R., Schenck-Gustafsson, K., Sellier, P., Stein, J. H., Thompson, P. L., Tzivoni, D. (2007). Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Elderly (SAGE). Circulation 115: 700-707 [Abstract] [Full Text]  
• Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., Kapadia, S. R., Nissen, S. E. (2007). Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. JAMA 297: 499-508 [Abstract] [Full Text]  
• Khush, K. K., Waters, D. D., Bittner, V., Deedwania, P. C., Kastelein, J. J.P., Lewis, S. J., Wenger, N. K. (2007). Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study. Circulation 115: 576-583 [Abstract] [Full Text]  
• Bullano, M. F., Kamat, S., Wertz, D. A., Borok, G. M., Gandhi, S. K., McDonough, K. L., Willey, V. J. (2007). Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting. Am J Health Syst Pharm 64: 276-284 [Abstract] [Full Text]  
• Houslay, E. S, Sarma, J., Uren, N. G (2007). The effect of intensive lipid lowering on coronary atheroma and clinical outcome. Heart 93: 149-151 [Abstract] [Full Text]  
• Penning-van Beest, F. J.A., Termorshuizen, F., Goettsch, W. G., Klungel, O. H., Kastelein, J. J.P., Herings, R. M.C. (2007). Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 28: 154-159 [Abstract] [Full Text]  
• Shor, R., Wainstein, J., Oz, D., Boaz, M., Matas, Z., Fux, A., Halabe, A. (2007). Low Serum LDL Cholesterol Levels and the Risk of Fever, Sepsis, and Malignancy. Annals of Clinical & Laboratory Science 37: 343-348 [Abstract] [Full Text]  
• Boodhwani, M., Mieno, S., Voisine, P., Feng, J., Sodha, N., Li, J., Sellke, F. W. (2006). High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. J. Thorac. Cardiovasc. Surg. 132: 1299-1306 [Abstract] [Full Text]  
• de Lusignan, S., Belsey, J., Hague, N., Dhoul, N., van Vlymen, J. (2006). Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study. J Public Health (Oxf) 28: 361-369 [Abstract] [Full Text]  
• Cuccurullo, C., Iezzi, A., Fazia, M. L., De Cesare, D., Di Francesco, A., Muraro, R., Bei, R., Ucchino, S., Spigonardo, F., Chiarelli, F., Schmidt, A. M., Cuccurullo, F., Mezzetti, A., Cipollone, F. (2006). Suppression of Rage as a Basis of Simvastatin-Dependent Plaque Stabilization in Type 2 Diabetes. Arterioscler. Thromb. Vasc. Bio. 26: 2716-2723 [Abstract] [Full Text]  
• Ritz, E., Wanner, C. (2006). Lipid Changes and Statins in Chronic Renal Insufficiency. J. Am. Soc. Nephrol. 17: S226-S230 [Abstract] [Full Text]  
• Cohen, J. S., East, J. E., Elkind, M. S.V., Khan, N. A., Mascitelli, L., Pezzetta, F., Welch, K.M.A., the SPARCL Investigators, , Kent, D. (2006). Statin Therapy after Stroke or Transient Ischemic Attack. NEJM 355: 2368-2371 [Full Text]  
• Davidson, M. H., McKenney, J. M., Shear, C. L., Revkin, J. H. (2006). Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels. J Am Coll Cardiol 48: 1774-1781 [Abstract] [Full Text]  
• McKenney, J. M., Davidson, M. H., Shear, C. L., Revkin, J. H. (2006). Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels on a Background of Atorvastatin. J Am Coll Cardiol 48: 1782-1790 [Abstract] [Full Text]  
• Milani, R. V., Lavie, C. J. (2006). Cholesteryl Ester Transfer Protein Inhibition: The Next Frontier in Combating Coronary Artery Disease?. J Am Coll Cardiol 48: 1791-1792 [Full Text]  
• Waters, D. D., LaRosa, J. C., Barter, P., Fruchart, J.-C., Gotto, A. M. Jr, Carter, R., Breazna, A., Kastelein, J. J.P., Grundy, S. M. (2006). Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study. J Am Coll Cardiol 48: 1793-1799 [Abstract] [Full Text]